- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01672255
Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)
February 12, 2024 updated by: Stephen N. Davis, MBBS, University of Maryland, Baltimore
Hypoglycemia Associated Autonomic Failure in Type 1 DM, SSRI and Exercise
Exercise is a cornerstone of diabetes management.
It helps reduce blood pressure, promote weight loss, lower insulin resistance and improve glucose and lipid (triglyceride and HDL-cholesterol) profiles.
Unfortunately, the benefits of exercise are often not embraced by diabetic individuals because of the fear of low blood sugar (hypoglycemia).
My laboratory has demonstrated that Autonomic nervous system (ANS) counterregulatory failure plays an important role in exercise associated hypoglycemia in Type 1 DM.
ANS responses are significantly reduced in Type 1 DM and are further blunted by antecedent episodes of hypoglycemia.
Furthermore, there is a large sexual dimorphism of reduced ANS responses during submaximal exercise in both Type 1 DM and healthy individuals that is unexplained.
Accumulating data are demonstrating that serotonergic pathways can regulate ANS discharge.
Generally, serotonergic pathways are inhibitory but both single and longer term administration of selective serotonin reuptake inhibitors (SSRI's) such as Prozac has been demonstrated to increase basal epinephrine levels and enhance baroreflex control of Sympathetic nervous system (SNS) activity.
What is unknown is whether fluoxetine can also enhance SNS responses and also override the large ANS sexual dimorphism present during sub maximal exercise.
Therefore, the purpose of this study is to determine if the SSRI fluoxetine (Prozac) can improve SNS responses during exercise.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
64
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maka Siamashvili, MD
- Phone Number: 410-706-5623
- Email: msiamashvili@som.umaryland.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland, Baltimore
-
Contact:
- Maka Siamashvili, MD
- Phone Number: 410-706-5623
-
Principal Investigator:
- Stephen N. Davis, MBBS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 32 (16 males, 16 females) Healthy controls aged 18-45 yr.
- 32 (16 males, 16 females) Type 1 diabetic patients aged 18-45 yr.
- HbA1c 6-10.0%
- Has been diagnosed Type 1 DM
- No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)
- Body mass index < 40kg • m-2
Exclusion Criteria:
- Pregnant women
- Subjects unable to give voluntary informed consent
- Subjects on anticoagulant drugs, anemic or with known bleeding diatheses
- Subjects taking any of the following medications will be excluded: Non-selective Beta Blockers, Sedative-Hypnotics, Anticonvulsants, Antiparkinsonian drugs, Antipsychotics, Antidepressants, Mood stabilizers, CNS Stimulants, Opioids, Hallucinogens
- Subjects with a recent medical illness
- Subjects with a history of hypertension, heart disease, cerebrovascular incidents
- Current tobacco use
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Trial 1-SSRI
90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac).
Repeat 90 minute exercise after 6 week treatment.
|
20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
Other Names:
|
Placebo Comparator: Trial 2-Placebo
90 minute exercise at baseline with 6 weeks treatment with placebo.
Repeat 90 minute exercise after 6 weeks treatment of placebo.
|
20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Catecholamines
Time Frame: During 90 minute experimental period
|
This change in catecholamines will be compared to another 90 minute experimental period after 8 weeks administration of SSRI or placebo.
|
During 90 minute experimental period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Stephen N. Davis, MBBS, University of Maryland, Baltimore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
August 17, 2012
First Submitted That Met QC Criteria
August 21, 2012
First Posted (Estimated)
August 24, 2012
Study Record Updates
Last Update Posted (Estimated)
February 14, 2024
Last Update Submitted That Met QC Criteria
February 12, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Diabetes Mellitus, Type 1
- Hypoglycemia
- Pure Autonomic Failure
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Selective Serotonin Reuptake Inhibitors
- Fluoxetine
Other Study ID Numbers
- HP-00044537; SSRI and Exercise
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Fluoxetine
-
Yale UniversityNational Institute of Mental Health (NIMH)RecruitingObsessive-Compulsive DisorderUnited States
-
Chen QianRecruiting
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...Terminated
-
Centre Hospitalier St AnneTerminated
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
University of Sao PauloNovartis; Fundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional...CompletedObsessive Compulsive DisorderBrazil